AGC Biologics has partnered with Rarity PBC to provide development and GMP manufacturing of a gene therapy aimed at treating a rare, life-threatening immune disorder.
AGC Biologics began its cell therapy process development and clinical manufacturing services on July 1, 2025, at its Yokohama Technical Center in Japan.
